Merck celebrates its 350th anniversary

MerckMerck, a leading science and technology company, will celebrate its 350th anniversary this year with customers, partners and employees under the motto "Past. Present. Future." In 1668, the pharmacist Friedrich Jacob Merck laid the cornerstone for what Merck is today - a vibrant, global science and technology company. "350 years, that's an incredible number, especially if you consider everything that has happened in the world of science between 1668 and today. We are proud of the many contributions Merck has made to research and development. And we will also continue to do exactly the same. In other words, we are infinitely curious about what is coming," said Stefan Oschmann, Executive Board Chairman and CEO of Merck.

A highlight of the anniversary year will be the "Curious2018 - Future Insight" conference in Darmstadt in mid-July 2018. This will be attended by more than 35 renowned international scientists - including five Nobel Prize laureates - who on three days will be presenting their work and discussing the future of science and technology. Merck is supporting this premiere event as the main sponsor. The speakers will present to an audience of around 1,000 guests from all over the world topics oriented to the main focal areas of the three Merck business sectors (Healthcare "Healthy Lives - new breakthrough therapies and diagnostics", Life Science "Life Reimagined - synthetic biology and beyond", and Performance Materials "Materials & Solutions - chemistry and beyond"). Other topics of the conference address questions regarding digitalization ("Vibrant Digital - the power of in silico") and new forms of collaboration ("Bright Future - new ways of working and collaborating").

"We are fighting cancer and other serious diseases. We are helping other companies to conduct research even more quickly and efficiently. And we are developing high-tech materials with which autonomous driving or foldable displays, for example, are becoming reality. We are doing all this in close partnership with top researchers around the globe. Therefore, we are very much looking forward to a huge celebration of research with the best of the best," said Stefan Oschmann.

Besides the five Nobel Prize-winning scientists - Joachim Frank (2017, Chemistry), Fraser Stoddart (2016, Chemistry), Bruce Beutler (2011, Medicine), Harald zur Hausen (2008, Medicine), Jean-Marie Lehn (1987, Chemistry) - further renowned representatives of the scientific and business communities, among others, will be present at "Curious2018 - Future Insight".

Another central event in Merck's anniversary year is the European ceremony on May 3, 2018 in a pavilion especially constructed for the celebrations. Around 900 guests from the worlds of politics and business are invited to this event in Darmstadt. Further regional ceremonies will take place in June in Shanghai, China and in October in Boston, USA.

In addition, as part of the European ceremony on May 3, the new Innovation Center will be officially opened. The newly designed and constructed building at the heart of Merck headquarters offers start-ups and company-internal innovation teams a five times larger area than was formerly available for working on innovation projects outside the existing business.

"It is a great joy to collaborate with young entrepreneurs. And who knows, one of the promoted business ideas might evolve some time into a company like Merck. After all, we also began as a start-up in 1668," said Stefan Oschmann.

Before Merck celebrates with external customers, partners and representatives of society, a celebration for employees will take place on April 18/19. This is planned for the around 50,000 people working at Merck worldwide and will extend over all continents for 24 hours.

"The celebration is a huge expression of our thanks to all our employees worldwide. With their work day by day, they ensure the success of our company. In Darmstadt we have many employees whose families have worked loyally for Merck over generations, which we highly esteem. Yet more and more talented people join Merck from all over the world, because they feel that Merck is a place where exciting things can be made to happen. In April, together with all of them, we will celebrate 350 years and the future," said Stefan Oschmann.

The other numerous events marking the 350th anniversary of Merck include the national "Jugend forscht" (Young Researchers) competition under the auspices of German Federal President Frank-Walter Steinmeier, which will take place in Darmstadt from May 24 to 27. The "Federal President's Award for Outstanding Work" is among the prestigious prizes awarded at the German national finals.

A highlight towards the end of the anniversary celebrations in autumn will be an Open Day on September 22, 2018 at global headquarters in Darmstadt. Interested visitors will then have the opportunity to take a look behind the scenes of the science and technology company Merck.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

The immune system: T cells are built for speed

Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The e...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Pfizer initiates pivotal Phase 3 program for inves…

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evalu...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...